金沙威尼斯欢乐娱人城
2014学年春季学期系列学术讲座之四
题目：Magnetic nanotechnology for medical diagnostics and drug development
报告人：Shan X. Wang
Director of the Stanford Center for Magnetic Nanotechnology,
Professor of Materials Science & Engineering, Stanford University
时间：2014年3月28日（周五），下午13:00-14:30 PM
地点：金沙威尼斯欢乐娱人城一楼邓祐才报告厅
Reproducible and multiplex protein assays are greatly desired to rapidly quantify multiple protein biomarkers in clinical samples to diagnose cancer, infectious diseases and many other diseases. We have now successfully applied a magneto-nanosensor diagnostic platform based on giant magnetoresistance (GMR) spin valve sensor arrays and magnetic nanoparticle (MNP) labels to the detection of relevant biological events in the form of multiplex protein assays (4-to 64-plex) with great speed (30 min. – 2 hours), sensitivity (1 picogram/milliliter concentration levels or below), selectivity, and economy . Good examples include commonly used cancer biomarkers such as PSA, AFP, CEA, CA125, and HE4, infectious viruses such as HPV, HIV, HCV and HBV, and various antibody isotypes.
For point of care applications, we have also demonstrated a rapid, multiplex immunoassay that eliminates the need for trained technicians to run multivariate in-vitro diagnostic tests. Furthermore, the platform can be battery-powered and ultraportable, and can be controlled by a smart phone with test results which can be communicated to doctor’s office over the Internet. The technology would allow the sophisticated multivariate assays commonly found in clinical laboratories to be run in resource limited settings by any individual, opening numerous new opportunities to improve healthcare.
We have also achieved the first demonstration of a nanolabel-based technology capable of rapidly isolating cross-reactive antibody binding events in a highly multiplex manner. By combining magnetic nanotechnology with immunology, we have devised an easy to use and rapid auto-assembly assay which is ideal for high-density screens of aberrant protein binding events. Such a technology has the potential to revolutionize the current practices in the proteomics and drug development community by providing researchers with the tools to rapidly investigate both on and off-target protein binding events. This technology is more sensitive and specific than label-free technologies (e.g., Surface Plasmon Resonance (SPR) based approaches such as Biacore), can be scaled up more readily, and consumes far less valuable reagents. It has also been extended to advanced reverse phase assay format in which multiple samples and multiple targets can be interrogated on a single chip.
Host：生科院强化挑战班
欢迎各位老师和同学积极参加！